Technology transfer showcase
Features on projects supported by Technology Transfer that have brought a product to market or have attracted a follow-on funder.
This project aims to analyse information about how stroke patients perform arm and hand movements as they play video games, and to provide feedback to patients and therapists.
Watch (3 min 58 s)
While it's been known for some time that the waste of the dust mite contains an allergy-causing protein, it's only now that the researchers have discovered a way to block this protein's action. By doing so, they hope to create an entirely new class of anti-asthma drug.
A team of surgeons and engineers are developing a robotic snake-like device for surgery called i-Snake®. It will be self-propelled, able to move through the body to its target, where the surgeon can operate it by remote control. The project aims to transform keyhole surgery.
What if red blood cells could be manufactured to order, creating a potentially limitless supply of tailored, infection-free cells? This is the key ambition of a team determined to make blood shortages a thing of the past.
The LV Prasad Eye Institute in Hyderabad, in partnership with Sheffield University, has been awarded funding to develop and use new biocompatible materials for a stem-cell-based therapy to restore sight in eyes where the cornea has been damaged by chemical injury or burns.
Research by Professor Bloom and his team has identified the role played by gut hormones in appetite control, and has been the starting point to develop a new drug to tackle obesity.
Dr Helen McShane at the University of Oxford and the Oxford-Emergent Tuberculosis Consortium Ltd are trialling the efficacy of a new TB vaccine candidate in South African infants.
Test kits developed by Diagnostics for the Real World could transform the diagnosis of chlamydia and other common infections.
Watch (7 min 22s)
How Trust-supported work at the Institute for Cancer Research, London could lead to a new drug to fight melanoma and other cancers.
Emergent BioSolutions has developed a single-dose, drinkable typhoid vaccine candidate that has shown considerable promise in phase II studies.
